Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer.

BACKGROUND

Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK

METHODS

We retrospectively analyzed the flow of 145 consecutive TKI-treated ALK

RESULTS

At the time of analysis, 70/144 (49%) evaluable patients were still alive. Attrition rates related to targeted treatments were approximately 25-30% and similar for administration of a second-generation (2G) ALK inhibitor (22%, 17/79) or any subsequent systemic therapy (27%, 27/96) after crizotinib, and for the administration of lorlatinib (27%, 6/22) or any subsequent systemic therapy (25%, 15/61) after any 2G TKI. The rate of chemotherapy implementation was 67% (62/93). Both administration of additional TKI (median overall survival [mOS] 59

CONCLUSIONS

Despite absence of regulatory obstacles and no requirement for specific acquired mutations, 25-30% of ALK

Informations de copyright

Copyright © 2021 Elsayed, Bozorgmehr, Kazdal, Volckmar, Sültmann, Fischer, Kriegsmann, Stenzinger, Thomas and Christopoulos.

Déclaration de conflit d'intérêts

FB: research funding from BMS and travel grants from BMS and MSD. DK: advisory board and speaker’s honoraria from AstraZeneca, BMS, Pfizer. HS: advisory board and speaker’s honoraria from Roche. JF: advisory board honoraria from Boehringer, Roche, Celgene and AstraZeneca. AS: advisory board honoraria from BMS, AstraZeneca, ThermoFisher, Novartis, speaker’s honoraria from BMS, Illumina, AstraZeneca, Novartis, ThermoFisher, MSD, Roche, and research funding from Chugai. MT: advisory board honoraria from Novartis, Lilly, BMS, MSD, Roche, Celgene, Takeda, AbbVie, Boehringer, speaker’s honoraria from Lilly, MSD, Takeda, research funding from AstraZeneca, BMS, Celgene, Novartis, Roche and travel grants from BMS, MSD, Novartis, Boehringer. PC: research funding from AstraZeneca, Novartis, Roche, Takeda, and advisory board/lecture fees from AstraZeneca, Boehringer Ingelheim, Chugai, Novartis, Pfizer, Roche, Takeda. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.